New Paper (Other): [Potent human neutralizing antibodies elicited by SARS-CoV-2 infection] about covid19-review HOT 1 OPEN

I reviewed that paper for my contribution to the "Neutralizing Antibodies" section.
I think they raised some important points in this paper:

1. Cross-reactivity often occurs outside of the RBD of the Spike protein. This has important implications for when other groups look at cross-reactivity and only look at spike protein in general. This also suggests that neutralizing antibodies developed for SARS-CoV and MERS-CoV will not work despite the similarity in protein structure.
2. Binding affinity does not reflect the capability to outcompete ACE2 binding
3. Neutralizing antibodies did not correlate with patient disease status.

Number 3 being the most significant one. Especially they mentioned that the patients with more severe disease actually had more potent neutralizing antibodies. This is also mentioned in this study here https://insight.jci.org/articles/view/123158. This begs the question of how useful their findings are in terms of therapeutic potential. They have not shown that these antibodies can protect a mouse or a human from infection or any other in vivo challenge. Until then, they only found antibodies that bind the target they screened for (they only looked for the RBD, nothing else) and inhibit ACE2 binding in vitro.

from covid19-review.